The development of deuterated drugs marks a significant milestone in the pharmaceutical industry. By incorporating deuterium, a heavier isotope of hydrogen, into drug molecules, researchers have found a way to enhance drug stability, improve pharmacokinetics, and potentially reduce side effects. The approval of the first deuterated drug, Austedo (deutetrabenazine), by the U.S. Food and Drug Administration (FDA) in 2017, opened new possibilities for drug development.
The Science Behind Deuteration
Deuterium (2H or D), a hydrogen isotope with a neutron in its nucleus, forms stronger carbon-deuterium (C-D) bonds compared to carbon-hydrogen (C-H) bonds. This difference arises from deuterium's higher atomic mass, which reduces vibrational frequency and increases bond stability. The kinetic isotope effect slows enzymatic cleavage of C-D bonds, altering drug metabolism. For example, replacing hydrogen with deuterium at metabolic "hotspots" can delay hepatic oxidation by cytochrome P450 enzymes, prolonging a drug's half-life and improving exposure. Unlike radical structural modifications, deuteration preserves a molecule's target-binding affinity while fine-tuning its pharmacokinetic profile. This makes it an attractive strategy for optimizing drugs with known efficacy but suboptimal dosing or safety profiles.
Austedo: The First FDA-Approved Deuterated Drug
Background of Austedo
Austedo (deutetrabenazine) was developed as a deuterated analog of tetrabenazine, a drug used to treat Huntington's disease (HD) and tardive dyskinesia. Huntington's disease is a progressive neurodegenerative disorder caused by a genetic mutation in the HTT gene, leading to the production of an abnormal huntingtin protein. This defective protein gradually damages nerve cells in the brain, particularly in the basal ganglia, which controls movement and cognition. Tetrabenazine is effective but has several limitations, including:
- Short half-life (about 4-8 hours): This requires multiple doses per day.
- Fluctuations in plasma drug concentration: This leads to inconsistent symptom control.
- Metabolism to active metabolites: This may contribute to side effects such as sedation, depression, and Parkinsonism.
The Development of Austedo
By replacing two hydrogen atoms with deuterium at key positions on tetrabenazine's methoxy groups, deutetrabenazine achieves a slower metabolic conversion to active metabolites. This modification extends its half-life to approximately 9-10 hours, enabling twice-daily dosing and reducing peak plasma concentrations linked to adverse effects. In 2017, the FDA approved deutetrabenazine for HD chorea and later for tardive dyskinesia. Clinical trials demonstrated comparable efficacy to tetrabenazine but with improved tolerability, and patients experienced fewer dose-related side effect. This success positioned deutetrabenazine as a blueprint for deuteration strategies in other therapeutic areas.
Fig. 1. The structures of Tetrabenazine and Austedo (deutetrabenazine).
Deutetrabenazine vs. Tetrabenazine
| Feature | Tetrabenazine | Austedo (Deutetrabenazine) |
|---|
| FDA Approval Year | 2008 | 2017 |
| Half-Life | About 4-8 hours | About 9-10 hours |
| Dosing Frequency | 3-4 times/day | 2 times/day |
| Metabolism | Rapidly metabolized to active metabolites | Slower metabolism due to deuterium substitution |
| Plasma Drug Stability | High fluctuations | More stable levels |
| Adverse Effects | Higher risk of sedation, depression | Lower risk due to improved metabolism |
| Clinical Benefit | Effective for chorea in HD | Similar efficacy but better tolerability |
Austedo proves that deuteration can successfully enhance drug properties without altering therapeutic effects. This success has paved the way for further research into deuterated drugs for other neurodegenerative and metabolic disorders, and encouraged further research into deuteration as a strategy for drug development.
Related Products from Alfa Chemistry
Beyond Austedo
The success of Austedo has spurred interest in the development of similar compounds. More and more deuterated drugs are being developed. Below is an overview of approved and investigational deuterated drugs:
- Deucravacitinib (Sotyktu): Approved by the FDA in 2022, deucravacitinib is a deuterated tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate-to-severe plaque psoriasis. Its deuterated structure contributes to improved selectivity and a favorable safety profile.
- CTP-543 (Deuruxolitinib): A deuterated form of ruxolitinib, this Janus kinase (JAK) inhibitor is under investigation for treating alopecia areata, an autoimmune disorder causing hair loss. Clinical trials have shown promising results in promoting hair regrowth.
- RT001: A deuterated form of linoleic acid ethyl ester, RT001 is in clinical trials for neurodegenerative diseases such as Friedreich's ataxia and amyotrophic lateral sclerosis (ALS). The deuteration aims to stabilize mitochondrial membranes and protect against oxidative damage.
- PXL065: The deuterium-stabilized (R)-enantiomer of pioglitazone, PXL065 is being developed for nonalcoholic steatohepatitis (NASH). The deuteration is intended to reduce side effects associated with the S-enantiomer while preserving therapeutic benefits.
- SP-3164: A deuterated form of Avadomide, SP-3164 is in preclinical development as a cereblon-binding protein degrader for treating lymphomas. Deuteration aims to stabilize the preferred S-enantiomer, enhancing binding affinity and therapeutic potential.
Related Products from Alfa Chemistry
Challenges and Future Directions
- Regulatory and Patent Considerations: While deuteration can improve drug properties, regulatory agencies must carefully assess whether the changes are substantial enough to grant new drug approvals. Patentability can also be challenging, as minor modifications to existing drugs may not always qualify for strong intellectual property protection.
- Cost of Development: Despite its benefits, deuteration involves additional synthetic and analytical challenges, which can increase the cost of drug development. Ensuring that the benefits outweigh the costs is crucial for widespread adoption.
- Expanding the Scope of Deuterated Drugs: Following Austedo, several other deuterated drugs have been in development, targeting conditions such as cancer, neurological disorders, and metabolic diseases. As research advances, more innovative applications of deuteration are expected to emerge.
Related Services from Alfa Chemistry
Please kindly note that our products and services are for research use only.
